PMID- 32954751
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 10
IP  - 2
DP  - 2021 Feb
TI  - Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as 
      first-line treatment for stage IV non-small cell lung cancer: a meta-analysis 
      based on randomized controlled trials.
PG  - 1154-1166
LID - 10.21037/apm-19-365 [doi]
AB  - BACKGROUND: Whether necitumumab combined with platinum-based chemotherapy (NC) 
      for treating stage IV non-small cell lung cancer (NSCLC) as a first-line 
      treatment could enhance antitumor effectiveness compared with platinum-based 
      chemotherapy alone (CA) treatment is still controversial. The antitumor 
      effectiveness and toxicity of the two treatments were compared in this 
      meta-analysis. METHODS: We searched in PubMed, ScienceDirect, Scopus, Web of 
      Science, Ovid MEDLINE, the Cochrane Library, Embase, and Google Scholar to 
      acquire applicable articles. The outcome indicators mainly included 
      progression-free survival (PFS), overall survival (OS) and adverse effects (AEs). 
      RESULTS: Eight articles based on 4 randomized controlled trials were obtained. 
      The NC group had a longer PFS [95% confidence interval (CI): 0.84-0.99, P=0.03] 
      and a higher disease control rate (DCR, 95% CI: 1.01-1.10, P=0.03) than those of 
      the CA group. OS (95% CI: 0.85-1.01, P=0.09) and the objective response rate 
      (ORR, 95% CI: 0.93-1.71, P=0.14) were similar in the NC and CA groups. 
      Nevertheless, in both quantity and extent, the NC treatment had more severe skin 
      rash, hypomagnesemia, and venous thromboembolism than those of the CA treatment. 
      Subanalysis suggested that the advantage of OS was more obvious in the NC group 
      than that in the CA group in patients with high epidermal growth factor receptor 
      (EGFR) expression. CONCLUSIONS: With a longer PFS and a higher DCR, NC treatment 
      seemed to be more suitable for treating stage IV NSCLC as first-line therapy, 
      especially for those with high EGFR expression, but its AEs could not be ignored.
FAU - Wang, Li
AU  - Wang L
AD  - Department of Thoracic Surgery, the Second Affiliated Hospital of Nanchang 
      University, Nanchang, China; Jiangxi Medical College, Nanchang University, 
      Nanchang, China.
FAU - Liao, Chen
AU  - Liao C
AD  - Department of Thoracic Surgery, the Second Affiliated Hospital of Nanchang 
      University, Nanchang, China; Jiangxi Medical College, Nanchang University, 
      Nanchang, China.
FAU - Li, Meng
AU  - Li M
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China; Department of 
      Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Zhang, Shujuan
AU  - Zhang S
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China; Department of 
      Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Yi, Fengming
AU  - Yi F
AD  - Department of Oncology, the Second Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Wei, Yiping
AU  - Wei Y
AD  - Department of Thoracic Surgery, the Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Yu, Jiao
AU  - Yu J
AD  - Department of Thoracic Surgery, the Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Zhang, Wenxiong
AU  - Zhang W
AD  - Department of Thoracic Surgery, the Second Affiliated Hospital of Nanchang 
      University, Nanchang, China. zwx123dr@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200915
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 2BT4C47RUI (necitumumab)
RN  - 49DFR088MY (Platinum)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - *Antineoplastic Agents/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Platinum/therapeutic use
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Necitumumab
OT  - chemotherapy
OT  - meta-analysis
OT  - non-small cell lung cancer (NSCLC)
OT  - platinum
OT  - stage IV
EDAT- 2020/09/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/21 08:40
PHST- 2019/10/13 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/09/21 08:40 [entrez]
AID - apm-19-365 [pii]
AID - 10.21037/apm-19-365 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2021 Feb;10(2):1154-1166. doi: 10.21037/apm-19-365. Epub 2020 
      Sep 15.